UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 162

Sortiert nach

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Link zum Volltext

Verfügbarkeit prüfen

Delivering precision oncology to patients with cancer

Nature Medicine, 2022-04, Vol.28 (4), p.658-665

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

Journal of clinical oncology, 2018-10, Vol.36 (30), p.3007-3014

2018

Link zum Volltext

Verfügbarkeit prüfen

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Cancers, 2021-06, Vol.13 (11), p.2824

2021

Link zum Volltext

Verfügbarkeit prüfen

Precision medicine in breast cancer: From clinical trials to clinical practice

Cancer treatment reviews, 2021-07, Vol.98, p.102223-102223, Article 102223

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Clinical cancer research, 2017-11, Vol.23 (21), p.6411-6420

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of the COVID-19 pandemic on cancer treatment and research

The Lancet. Haematology, 2020-06, Vol.7 (6), p.e432-e435

2020

Link zum Volltext

Verfügbarkeit prüfen

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

British journal of cancer, 2020-10, Vol.123 (8), p.1235-1243

2020

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

British journal of cancer, 2022-04, Vol.126 (7), p.1010-1017

2022

Link zum Volltext

Verfügbarkeit prüfen

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231183679-17588359231183679

2023

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

Supportive care in cancer, 2021-11, Vol.29 (11), p.6271-6278

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

Breast cancer research : BCR, 2020-09, Vol.22 (1), p.1-11, Article 97

2020

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-11, Vol.14 (1), p.7018-7018, Article 7018

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapies of solid cancers: new options, new challenges

Current opinion in oncology, 2013-05, Vol.25 (3), p.296-304

2013

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-12, Vol.14 (1), p.8223-8223, Article 8223

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine

Discovery medicine, 2014-02, Vol.17 (92), p.81-91

2014

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review

Expert review of anticancer therapy, 2014-06, Vol.14 (6), p.649-665

2014

Link zum Volltext

Verfügbarkeit prüfen

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer

Cancers, 2022-11, Vol.14 (21), p.5467

2022

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer

Breast (Edinburgh), 2018-06, Vol.39, p.14-18

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of tumor sequencing on the use of anticancer drugs

Current opinion in oncology, 2014-05, Vol.26 (3), p.347-356

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Investigational new drugs, 2015-06, Vol.33 (3), p.611-620

2015

Link zum Volltext

Verfügbarkeit prüfen

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients

NPJ breast cancer, 2020-12, Vol.6 (1), p.64-64, Article 64

2020

Link zum Volltext

Verfügbarkeit prüfen

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

Cancers, 2020-02, Vol.12 (2), p.512

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 162

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(154)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(72)
Oncology
(64)
Humans
(58)
Female
(37)
Breast Cancer
(32)
Middle Aged
(22)
Adult
(21)
Male
(21)
Aged
(18)
Tumors
(18)
Breast Neoplasms - Drug Therapy
(17)
Metastasis
(16)
Patients
(16)
Antineoplastic Agents - Therapeutic Use
(14)
Mutation
(12)
Neoplasms - Drug Therapy
(11)
Aged, 80 And Over
(10)
Breast Neoplasms - Pathology
(10)
Cancer Therapies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Delivering precision oncology to patients with cancer

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Precision medicine in breast cancer: From clinical trials to clinical practice

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Effect of the COVID-19 pandemic on cancer treatment and research

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Targeted therapies of solid cancers: new options, new challenges

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations

Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer

Impact of tumor sequencing on the use of anticancer drugs

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

Suchergebnisse filtern